A large-scale international study led by Mount Sinai researchers has yielded the first risk score to help predict mortality among patients with atrial fibrillation after undergoing a successful transcatheter aortic valve replacement (TAVR). They found that the mortality rate was more than double in the “moderate-risk” patients and triple in the “high-risk” group compared to patients in the “low-risk” group.
The ENVISAGE-TAVI AF trial was the largest of its kind. The results were announced Sunday, August 28, as a late-breaking clinical trial at the European Society of Cardiology Congress (ESC Congress 2022).
“Our study focuses solely on high-risk TAVR patients with atrial fibrillation, which is a well-recognized surrogate of unfavorable prognosis,” says lead investigator George Dangas, MD, PhD, Professor of Medicine and Director of Cardiovascular Innovation at The Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai. “Although past research has been mostly focused on procedure risks, this new risk assessment tool focuses on how to stratify patients after completion of successful TAVR when they are ready for discharge, to improve outcomes.”
TAVR is a minimally invasive procedure that is an alternative to open heart surgery to replace the aortic valve of patients with symptomatic aortic stenosis. Before the procedure, physicians assess patients’ risk of death. This helps doctors better explain the risks to the patient, guide decision-making before and after the procedure, and choose the most appropriate therapies. However, there is no definitive risk score for TAVR.
Surgeons often rely on the Society of Thoracic Surgeons (STS) risk score that was developed for open heart surgery, or other similar risk scores for this procedure. This score has limitations for TAVR because it was derived from cohorts of patients undergoing surgical aortic valve replacement.
Prior attempts to create a risk score for TAVR patients were unsuccessful, and took place nearly a decade ago when the procedure was new and mainly used in an older patient population. This trial was based on a data set in an updated population. The risk score, the researchers say, applies for patients who underwent recent TAVR in the last five years and who have atrial fibrillation.
Mount Sinai researchers led the international ENVISAGE-TAVI trial across 173 centers in 14 countries to compare the safety and efficacy of different therapies in AF/TAVR patients who need oral anticoagulation. They analyzed 1,426 patients starting 5 to 12 days after TAVR and followed them up to one year to evaluate predictors of mortality.
Of the 178 patients (12.5 percent) who died within that timeframe, most were over age 64; had kidney disease and/or heart failure; higher weight; had non-paroxysmal AF (a common, persistent, and permanent AF lasting for more than a week); consumed more than three alcoholic drinks per day; and had a history of major bleeding or predisposition to bleeding during the procedure.
Investigators assigned a risk level to each of those predictors. Once they calculated total risk, they classified patients into three categories: low risk (between 0-10), moderate risk (between 11-15), and high risk (above 16). They validated the risk score and found that the mortality rate was more than double in the moderate-risk patients (10.1 percent) and triple in the high-risk group (17 percent) compared to the low-risk group (4.8 percent).
“We will continue to perform focused analyses on high-risk TAVR patients based on combinations of different/other clinical risks to enhance our understanding of patient risks after TAVR so we can then plan clinical investigations on improving prognosis,” adds Dangas.
The ENVISAGE TAVI-AF study is part of EDOSURE, which is an extensive clinical research program for Daiichi-Sankyo’s direct oral anticoagulant edoxaban. The program comprises more than 10 randomized controlled trials, registries, and non-interventional studies in a broad range of cardiovascular conditions, patient types and clinical settings in atrial fibrillation and venous thromboembolism, involving over 100,000 patients worldwide. In 2021, some results from the trial were published in the New England Journal of Medicine.